Hikal Stock Screener | Share Price & Fundamental Analysis
HIKAL
Pharmaceuticals
Screen Hikal share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹225.22
▼
-1.74 (-0.77%)
Share Price BSE
₹225.20
▼
-1.85 (-0.81%)
Market Cap
₹2,797.94 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.34
EPS (TTM)
₹7.36
Dividend Yield
0.35%
Debt to Equity
0.65
52W High
₹432.90
52W Low
₹219.20
Operating Margin
2.00%
Profit Margin
-11.01%
Revenue (TTM)
₹318.00
EBITDA
₹7.00
Net Income
₹-35.00
Total Assets
₹2,529.00
Total Equity
₹1,262.00
Hikal Share Price History - Stock Screener Chart
Screen HIKAL historical share price movements with interactive charts. Analyze price trends and patterns.
Hikal Company Profile - Fundamental Screener
Screen Hikal company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for HIKAL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE475B01022
Hikal Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen HIKAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,529 | 2,487 | 2,386 | 2,213 | 1,913 | 1,768 | 1,686 | 1,542 | 1,380 | 1,275 |
| Current Assets | 995 | 967 | 939 | 964 | 879 | 775 | 830 | 690 | 577 | 467 |
| Fixed Assets | 1,365 | 1,071 | 948 | 880 | 713 | 735 | 713 | 634 | 668 | 623 |
| Liabilities | ||||||||||
| Total Liabilities | 2,529 | 2,487 | 2,386 | 2,213 | 1,913 | 1,768 | 1,686 | 1,542 | 1,380 | 1,275 |
| Current Liabilities | 477 | 543 | 591 | 376 | 323 | 355 | 327 | 312 | 334 | 337 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,262 | 1,188 | 1,134 | 1,068 | 933 | 817 | 756 | 669 | 605 | 564 |
| Share Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 16 | 16 | 16 |
| Reserves & Surplus | 1,238 | 1,163 | 1,109 | 1,043 | 909 | 792 | 732 | 653 | 589 | 547 |
Screen HIKAL income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 318 | 372 | 551 | 443 | 451 | 404 | 513 | 439 | 432 | 387 | 538 | 541 | 558 | 375 | 501 |
| Expenses | 311 | 355 | 429 | 376 | 378 | 349 | 420 | 383 | 377 | 338 | 457 | 466 | 489 | 356 | 441 |
| EBITDA | 7 | 17 | 122 | 67 | 73 | 56 | 94 | 56 | 55 | 49 | 81 | 75 | 69 | 19 | 60 |
| Operating Profit % | 2.00% | 4.00% | 22.00% | 14.00% | 16.00% | 14.00% | 18.00% | 13.00% | 12.00% | 13.00% | 15.00% | 14.00% | 12.00% | 4.00% | 12.00% |
| Depreciation | 41 | 39 | 38 | 33 | 32 | 32 | 32 | 29 | 29 | 28 | 27 | 28 | 27 | 27 | 24 |
| Interest | 15 | 17 | 18 | 19 | 19 | 20 | 15 | 14 | 13 | 14 | 13 | 13 | 11 | 11 | 8 |
| Profit Before Tax | -47 | -30 | 68 | 24 | 25 | 7 | 47 | 22 | 17 | 10 | 49 | 36 | 33 | -12 | 29 |
| Tax | -12 | -8 | 18 | 7 | 7 | 2 | 13 | 6 | 4 | 3 | 13 | 9 | 8 | -3 | 8 |
| Net Profit | -35 | -22 | 50 | 17 | 18 | 5 | 34 | 16 | 13 | 7 | 36 | 26 | 25 | -9 | 21 |
| EPS | -2.83 | -1.82 | 4.07 | 1.39 | 1.48 | 0.41 | 2.76 | 1.31 | 1.02 | 0.56 | 2.92 | 2.14 | 2.01 | -0.72 | 1.68 |
Hikal Cash Flow Screener - Liquidity Fundamentals
Screen HIKAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 280 | 187 | 315 | 294 | 229 | 285 | 186 | 139 | 164 | 186 |
| Investing Activities | -137 | -174 | -292 | -284 | -156 | -164 | -125 | -110 | -102 | -64 |
| Financing Activities | -144 | -27 | -8 | -6 | -97 | -101 | -55 | -25 | -63 | -124 |
| Net Cash Flow | 0 | -14 | 15 | 4 | -24 | 20 | 6 | 4 | -2 | -2 |
Screen HIKAL shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% |
| FII Holding | 5.69% | 5.36% | 4.23% | 6.55% | 6.67% | 6.78% | 6.06% | 0.00% |
| DII Holding | 3.80% | 4.02% | 5.16% | 3.53% | 3.17% | 3.58% | 3.48% | 2.19% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.57% | 16.75% | 16.66% | 16.45% | 16.31% | 15.81% | 16.64% | 18.72% |
| Other Holding | 5.08% | 5.02% | 5.10% | 4.62% | 5.01% | 4.99% | 4.97% | 10.25% |
| Shareholder Count | 68,907 | 71,391 | 73,404 | 71,840 | 70,978 | 71,912 | 71,801 | 75,167 |
Hikal Dividend Screener - Share Yield Analysis
Screen HIKAL dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.80 | 0.35% |
| 2024-March | ₹1.20 | 0.30% |
| 2023-March | ₹1.20 | 0.45% |
| 2022-March | ₹1.60 | 0.57% |
| 2021-March | ₹2.00 | 0.50% |
| 2020-March | ₹1.20 | 0.84% |
| 2019-March | ₹1.20 | 1.72% |
| 2018-March | ₹1.20 | 0.69% |
| 2017-March | ₹1.20 | 0.87% |
Hikal Index Membership - Market Screener Classification
Screen HIKAL by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Hikal Market Events Screener - Corporate Actions
Screen HIKAL market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.60 /share | 9.00% | ||
| Annual General Meeting | NA | -14.46% | ||
| Dividend | ₹ 0.80 /share | -37.12% | ||
| Annual General Meeting | NA | 17.36% | ||
| Dividend | ₹ 0.40 /share | -2.48% | ||
| Dividend | ₹ 0.60 /share | 12.32% | ||
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.76% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -6.81% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | 2.48% |
| 2025-02-07 | 2025-02-08 | Dividend | ₹ 0.60 /share | 5.04% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 6.12% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 1.74% |
| 2024-02-20 | 2024-02-20 | Dividend | ₹ 0.60 /share | -2.64% |
| 2023-02-14 | 2023-02-14 | Dividend | ₹ 0.60 /share | -6.05% |
| 2022-02-23 | 2022-02-24 | Dividend | ₹ 1.20 /share | -11.56% |
Hikal Competitors Screener - Peer Comparison
Screen HIKAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Hikal Company Announcements - News Screener
Screen HIKAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Closure of Trading Window | View |
| 2026-01-01 | Disclosure Under Regulation 30 Of SEBI Listing Regulations | View |
| 2025-12-11 | Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-05 | Intimation Under Regulation 7 (2) Of SEBI Prohibition Of Insider Trading Regulations 2015 | View |
| 2025-12-04 | Disclosure Under Regulation 30 Of SEBI Listing Regulations | View |
| 2025-12-03 | Intimation Under Regulation 30 30A Of SEBI Listing Regulations. | View |
| 2025-12-03 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-03 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-03 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | View |
| 2025-11-29 | Submission Of Copy Of Reminder Letters Sent To Shareholders Regarding Unclaimed Interim Dividend 2018-19 And Subsequent Newspaper Publication | View |
| 2025-11-25 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-11-19 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-13 | Submission Of Unaudited Standalone And Consolidated Financial Results For The Quarter And The Half Year Ended September 30 2025 | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-13 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-06 | Intimation Of Cancellation Of Earnings Group Conference Call | View |